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Abstract
Objective—To assess lung cancer risk in SLE, relative to demographics, drug exposures,
smoking, and disease activity.
Methods—We analyzed data from 14 SLE cohorts. We calculated adjusted hazard ratio (HR)
estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication
exposures, and cumulative disease activity (mean adjusted SLE Disease Activity, SLEDAI,
scores). This project was approved by the ethics boards of all participating institutions, including
the institutional review board of the McGill University Health Centre. The ethics approval Number
for the Cancer Risk study is GEN-06-031.

Author Manuscript

Results—Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer
cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung-cancer free
SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline,
versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated
with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects
of all drugs were relatively imprecise but did not point towards any drug exposures as strong lung
cancer risk factors.
Conclusion—We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE,
although drug risk estimates were relatively imprecise. Smoking may be the most significant
modifiable lung cancer risk factor in SLE.

Author Manuscript
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Introduction
Recent data have highlighted the increase in cancer in SLE over-all; lung cancer specifically
is 30–50% more common in SLE patients than their sex and age-matched counterparts.1 Our
objective was to assess lung cancer risk in SLE, comparing SLE patients with and without
lung cancer regarding demographics, drug exposures, and disease activity.

Materials and Methods
Author Manuscript

Since approximately 2000, we have been working with investigators from the Systemic
Lupus International Collaborating Clinics (SLICC) and other research networks, to further
elucidate cancer risk in SLE. The current cohort analysis of lung cancer risk factors is based
on 14 centres that were able to provide detailed information on drug use, disease activity,
and other factors. These centres were Canadian (Halifax, Calgary, Montreal, Toronto,
Winnipeg), American (Baltimore, Chicago, two in New York, San Francisco) centres abroad
(Birmingham and London UK, Sweden, and Seoul Korea). At all these centres, cancer cases
were determined on the basis of linkage of the patients to the appropriate tumor registries.
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We used Cox proportional hazards regression to calculate the hazard ratio (HR) for lung
cancer risk in SLE, relative to their exposure in terms of demographics (sex, race/ethnicity,
and age, as a continuous time-dependent variable), smoking status, and time-dependent
medication exposures.

Author Manuscript

We also adjusted for time-dependent cumulative disease activity, captured using mean
adjusted SLE Disease Activity Index (SLEDAI) scores, which involve calculating the area
under the curve between two SLEDAI scores as the average of the values at those two visits,
multiplied by the length of time between the two visits. All the calculated areas are then
summed, and divided by the total length of the time period. The adjusted mean SLEDAI has
the same units as SLEDAI, and is interpreted in the same way. The adjusted mean SLEDAI
has been shown to be a valid measure of cumulative SLE activity over time2. To aid in
interpretation, the mean adjusted SLEDAI score was categorized within quartiles. At one
centre (University of California San Francisco), disease activity was captured only with selfreport items.3 Thus at this centre the variable for cumulative SLE disease activity was
similarly categorized within quartiles. The time-dependent disease activity in our model
reflected whether or not a patient had reached the highest quartile of cumulative disease
activity. We also controlled for any prior record of pulmonary fibrosis, based on the
SLICC/ACR Damage Index, using a dichotomous time-dependent variable. This was done
since it has been suggested that pulmonary fibrosis may predispose to lung cancer.4

Author Manuscript

Time zero for the observation interval was SLE diagnosis, so that our analyses adjusted for
SLE duration (with left-censoring for the time from SLE diagnosis to cohort entry, when
relevant, to avoid immortal time bias5). The use of SLE duration as the time axis was chosen
because our earlier work suggested that cancer risk in SLE depends on SLE duration, in a
non-linear way.1 However, we did perform a sensitivity analysis where age was the time axis
(and SLE duration was a model covariate).
We included lung cancers occurring after entry into the lupus cohort and up to the time of
cohort exit (defined by death, cancer event, or date of last visit). Patients who developed a
cancer other than lung cancer during the observation interval, were right-censored at that
time.
Additionally, a sub-analysis was also performed for 6 centers where more precise, timedependent data on smoking exposure had been collected (Sweden, San Francisco, Montreal,
Halifax, Toronto and Winnipeg), in order to measure the effect of smoking intensity (in
terms of a dose-effect of pack-years). Those analyses included 11 cases of lung cancer and
724 cancer-free subjects.

Author Manuscript

Results
Across all the SLE cohorts that participated in our study, 49 new lung cancer cases occurred
and were included in our analyses. Compared to SLE controls without cancer (Table 1),
persons with SLE with lung cancer cases were more likely to be white (84.8% versus 61.8%
in non-lung cancer SLE controls), older at cohort entry (mean 51.2 and median 52.2 years;
versus mean 38.2, median 36.8 years in controls) and male (20.4% of lung, 95% CI 10.2,
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34.3 versus 9.2%, 95% CI 8.4, 10) of the remaining cohort). At cohort entry, the mean
disease duration was similar, while the median disease duration in lung cancer cases was 1.1
years, versus 3.1 years in SLE patients that did not develop cancer. The vast majority
(84.2%) of the lung cancer cases in SLE were ever-smokers at baseline, versus 40.1% of the
SLE patients who did not develop lung cancer.
Among lung cancer cases, 59.0% had high disease activity (that is, a disease activity within
the highest quartile) at baseline (95% confidence interval, CI 42.1,74.4%), in contrast to
only 40.8% (95% CI 39.4, 42.3) of SLE patients that went on to remain free of lung cancer.
The average SLE duration at time of lung cancer diagnosis was 14.2 years.

Author Manuscript

Regarding the medication profiles in the SLE patients who developed lung cancer versus
those who did not, none of the patients had been exposed to cyclophosphamide prior to a
lung cancer. In both univariate and adjusted models (Table 2), the principal factors
associated with lung cancer risk were ever smoking (at cohort entry) and current age. There
was no definitive evidence for greater cancer risk in SLE patients with higher cumulative
disease activity over time. The estimated adjusted effects of all drugs were relatively
imprecise. In a sensitivity analysis using age as the time axis, the results were similar.
In the sub-analyses, based on centers where pack-years had been measured, for smokers at
cohort entry who went on to develop lung cancer, the median number of pack-years of
smoking accumulated at baseline was 25 (mean 28.2, 95% CI 11.1, 45.2) pack-years, versus
8 (mean 11.9, 95% CI 10.9, 12.9) for smokers who remained cancer-free (n = 724).
Adjusting for current age, there was an increase in the HR of lung cancer equal to 1.04 (95%
CI 1.02, 1.05) for each additional pack-year.

Author Manuscript

Discussion

Author Manuscript

Cancer is an important outcome for SLE patients6. In our analyses, we saw no clear
evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates
were relatively imprecise. It is worth noting in particular that none of the lung cancer cases
had a history of cyclophosphamide exposure. Smoking appeared to be the most significant
modifiable lung cancer risk factor in SLE. Among lung cancer cases, 59.0% were in the
highest SLEDAI quartile at baseline versus 40.8% of SLE patients that remained lungcancer free. Adjusted analyses were consistent with a possible trend for greater cancer risk
in subjects within the highest quartile of SLE activity but the confidence interval for both the
unadjusted and adjusted HR estimates included the null value. In our sample, detailed
smoking exposure was only available on 11 lung cancer patients and 724 controls.
Fortunately, we were still able to show the expected dose-related effects, in this subgroup
analysis.”
Lung cancer is one of the most common malignancies in the general population, and the
five-year survival associated with advanced stages of this disease is poor. Lung cancer is in
fact the second most common lung cancer to occur in SLE. Patients with SLE are at greater
risk not only for developing lung cancer, but also for dying from it; previous analyses have
suggested a standardized mortality ratio for lung cancer of 2.3 (95% CI 1.6–3.0) in SLE
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versus the general population.7 It is thus very important to understand what drives lung
cancer risk in systemic autoimmune rheumatic diseases such as SLE. According to data
published by the SEER, adenocarcinoma is the most frequent histologic type of lung cancer
in women and men (41% and 33%, respectively), followed by squamous cell carcinoma
(15% and 24% in women and men respectively)8, 9. The remaining types (large cell, small
cell and others) are roughly equal in males and in females (representing about 45% of the
remaining cancer types. In the predominantly female SLE population, we have previously
published that adenocarcinoma was indeed the most common carcinoma, making up half of
the lung cancers in SLE, in males and in females. Squamous cell carcinoma was also the
second most common histology type, and made up 27% of the lung cancer histology in
female SLE patients, and 17% of the lung cancer histology in male patients. The percentage
of squamous cell carcinomas in females with SLE is higher than the percent of this
histologic type in general population of female lung cancers (15%; the 95% confidence
interval for the difference between proportions is −0.02, 0.27 and thus just scarcely includes
the null value). It is interesting that in our prior publication of lung cancer histology in SLE,
there were no large cell lung cancers noted, while about 9% of lung cancers in the general
population are large-cell carcinoma.

Author Manuscript

In the general population, small cell and squamous cell carcinomas are nearly always
associated with smoking10. Squamous cell carcinoma rates have been declining in males but
gradually increasing in females, possibly related to the increasing number of females that
smoked after the 1950’s11. A recent study published by the National Cancer Registry of
Ireland calculated that from 1994 to 2009 the incidence of squamous cell lung carcinoma in
women has increased by 1.3% annually. However, at the same time, the incidence of
adenocarcinoma in women has increased by even more (6.5%) annually12,13. Thus, it is
intriguing that there should be a higher than expected number of squamous cell cancers in
female SLE patients, while the percentage of adenocarcinoma in SLE seems to be what is
expected.

Author Manuscript

We have recently reviewed the evidence to guide cancer screening in SLE14. There are no
original research studies directly comparing cancer screening strategies in SLE, and most
authors recommend that SLE patients adhere to general population screening measures
Interestingly, the US Preventive Services Task Force recommended annual low-dose
computed tomography of the chest for adults aged 55 to 80 years who have a 30 pack-year
smoking history and currently smoke or have quit within the past 15 years (based on Grade
B evidence)15. Admittedly, this has been contested by the American Academy of Family
Physicians. Still, evidence suggests that women may be more susceptible to the carcinogenic
effects of smoking versus men.16 It seems reasonable that SLE patients with the specified
smoking history follow local recommendations for cancer screening; this decision could be
made by the patients’ primary care doctor, who is generally in charge of cancer screening.
Regardless of screening, emphasizing the importance of smoking cessation in SLE is
critical.
In conclusion, smoking appears to be the most significant modifiable risk factor for lung
cancer in SLE. For obvious reasons, those who care for SLE patients should continue to
actively counsel tobacco cessation in patients who smoke. Additional studies may also help
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determine the relative distribution of stages of lung cancer in SLE and understand the reason
for the increased mortality risk from lung cancer in SLE.
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Characteristics of lung cancer cases versus cancer-free SLE subjects
Variables

Lung Cancer Cases (n = 49)

Cancer-free (n = 4,938)

Mean age (in years) at cohort entry

51.2 (47.3, 55.1)*

38.2 (37.8, 38.6)

Percent male

20.4 (10.2, 34.3)

9.2 (8.4, 10)

Percent white

84.8 (71.1, 93.7)

61.8 (60.4, 63.1)

5.4 (3.0, 7.7)

6 (5.7, 6.2)

84.2 (68.7, 94)

40.1 (38.7, 41.5)

28.2 (11.1, 45.2)

11.6 (10.6, 12.6)

Percent positive for dsDNA at cohort entry

16.7 (7, 31.4)

27.1 (25.9, 28.4)

Percent with high disease activity at cohort entry***

59 (42.1, 74.4)

40.8 (39.4, 42.3)

0 (0, 9.7)*

1.7 (1.4, 2.2)

Mean disease duration at entry, in years
Percent ever smoking at cohort entry
Mean pack-years at entry (in smokers)**

Percent with pulmonary fibrosis at entry****

Author Manuscript

*

Brackets indicate 95% confidence intervals (CIs) aside from pulmonary fibrosis, where since none of the cancer cases had pulmonary fibrosis at
entry, we only have uncertainty on one side of the interval, hence we have a one-sided 97.5% interval, rather than a 95% CI.

**

A sub-analysis was also performed for 6 centers where more precise, time-dependent data on smoking exposure had been collected: Sweden, San
Francisco, Montreal, Halifax, Toronto and Winnipeg. Those analyses included 11 cases of lung cancer and 724 cancer-free subjects.

***

Except in one center (UCSF) where self-report items were used, SLE activity was assessed by the mean adjusted SLE disease activity index
(SLEDAI-2K), and categorized within quartiles over the full observation period.

****

Pulmonary fibrosis was assessed by the relevant item on the SLICC/ACR Damage Index.
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Unadjusted and adjusted hazard ratio estimates for lung cancer in systemic lupus
Variable

Unadjusted Hazard Ratios(95% CI)

Adjusted Hazard Ratios(95% CI)

1.01 (0.97, 1.05)

1.03 (0.97, 1.09)

Age (years)

1.09 (l.07, 1.12)

1.09 (1.06, 1.12)

Male

2.59 (1.20, 5.56)

1.13 (0.46, 2.74)

White

1.97 (0.85, 4.55)

2.10 (0.56, 7.93)

Smoking ever

6.92 (2.87, 16.7)

6.35 (2.43, 16.6)

dsDNA antibody positivity (weighted average)

0.21 (0.06, 0.72)

0.42 (0.11, 1.57)

Steroids ever

0.86 (0.41, 1.82)

0.60 (0.17, 2.15)

Cumulative steroid ≥3.5 grams

1.01 (0.51, 2.02)

1.92 (0.69, 5.33)

Cumulative cyclophosphamide ≥ 6 grams

0.28 (0.03, 2.49)

0.17 (0.03, 1.00)

Azathioprine ever

0.71 (0.29, 1.74)

0.68 (0.08, 5.63)

Azathioprine use ≥ 1 year

0.76 (0.28, 2.04)

1.81 (0.16, 21.0)

Methotrexate ever

0.67 (0.20, 2.20)

1.14 (0.32, 4.02)

Mycophenolate ever

0.73 (0.14, 3.74)

1.43 (0.39, 5.20)

NSAIDS ever

0.57 (0.28, 1.16)

0.57 (0.25, 1.26)

Antimalarial use ever

0.91 (0.43, 1.90)

1.65 (0.66, 4.15)

Cumulative antimalarial use ≥5 years

0.73 (0.32, 1.69)

0.55 (0.20, 1.51)

SLE activity top quartile*

0.93 (0.42, 2.04)

1.29 (0.64, 2.58)

Pulmonary fibrosis**

3.29 (0.86, 12.6)

2.41 (0.63, 9.22)

Calendar year
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*

Except in one center (UCSF) where self-report items were used, SLE activity is assessed by the mean adjusted SLE disease activity index
(SLEDAI), and categorized within quartiles over the full observation period.

**
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Pulmonary fibrosis was assessed by the relevant item on the SLICC/ACR Damage Index.
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